<DOC>
	<DOCNO>NCT01914744</DOCNO>
	<brief_summary>The aim study prove superiority entecavir lamivudine prevent risk hepatitis B virus reactivation patient non-Hodgkin lymphoma CHOP/R-CHOP .</brief_summary>
	<brief_title>Entecavir Versus Lamivudine Preventing Risk Hepatitis B Reactivation NHL</brief_title>
	<detailed_description>In china , previous study show patient non-Hodgkin lymphoma ( NHL ) likely hepatitis B virus ( HBV ) infection . The risk HBV reactivation high patient treat CHOP , especially combination rituximab . The aim study compare entecavir lamivudine , 2 commonly use anti-virus agent , prevent risk HBV reactivation patient NHL CHOP/R-CHOP .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>Previously untreated NHL suitable CHOP/RCHOP treatment Age range 1880 year old HBsAg positive high level HBV DNA Eastern Cooperative Oncology Group performance status 02 Life expectancy 3 month Adequate organ function Primary secondary central nervous system involvement With hepatitis C virus infection Previous serious cardiac disease History malignancies except cure basal cell carcinoma skin carcinoma insitu uterine cervix Pregnant lactate woman Serious uncontrolled disease intercurrent infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>NHL</keyword>
	<keyword>HBV</keyword>
	<keyword>entecavir</keyword>
	<keyword>lamivudine</keyword>
</DOC>